Safety and Pharmacokinetics of Multiple 750-Milligram Doses of Intravenous Levofloxacin in Healthy Volunteers

ANDREW T. CHOW,* CYNTHIA FOWLER, R. REX WILLIAMS, NANCY MORGAN, SUSAN KAMINSKI, AND JAYA NATARAJAN

The Robert Wood Johnson Pharmaceutical Research Institute, Raritan, New Jersey 08869

Received 10 August 2000/Returned for modification 29 January 2001/Accepted 3 April 2001

The safety and pharmacokinetics of a once-daily high intravenous dose of levofloxacin (750 mg) in 18 healthy volunteers were studied in a double-blind, randomized, placebo-controlled, single-center parallel group study. Levofloxacin was well tolerated, and higher maximum concentration of drug in serum and area under the concentration-time curve values were achieved. For difficult-to-treat infections, high daily doses of levofloxacin may be beneficial, and intravenous administration may be preferred in certain clinical settings, such as when treating patients in intensive care units, warranting further evaluation.

A levofloxacin regimen of 500 mg administered once daily has been efficacious in the treatment of respiratory and uncomplicated skin infections (6, 7, 10–12). However, infections that are more difficult to treat (i.e., complicated skin and skin structure infections, bacterial endocarditis, and nosocomial pneumonia) may necessitate higher daily doses of levofloxacin. The higher dose provides greater confidence in treating infections due to organisms for which drug MICs are high or patients with compromised vasculature that limits perfusion of the infection site. Having established the safety and pharmacokinetics of a 750-mg oral dose of levofloxacin (3), we conducted a pilot investigation to evaluate the safety and pharmacokinetics of 750 mg of intravenous (i.v.) levofloxacin administered as a single dose and then once daily for 7 days.

(This study was presented, in part, at the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, 28 September to 1 October 1997, Toronto, Canada.)

Eighteen healthy male and female volunteers, ages 26 to 54, participated in the study after granting written, informed consent as approved by the local institutional review board. Subjects were judged healthy on the basis of normal findings on medical history, physical examination, clinical laboratory tests, and electrocardiography (ECG). Eligibility for study participation also included no relevant history of chronic illness and no acute illness 7 days prior to the study’s commencement. In addition, subjects were not to have ingested alcoholic beverages or caffeine- or methylxanthine-containing substances 48 h prior to or during the study.

The study was conducted as a single-center, double-blind, randomized, placebo-controlled, parallel group study. Subjects were randomized in a 2:1 ratio to receive either levofloxacin (n = 12) or a placebo (n = 6) by i.v. infusion over 1.5 h. On study day 1, a single i.v. infusion was administered, followed by a washout phase (days 2 and 3). From study day 4 through study day 10, 7 once-daily i.v. infusions were administered.

The safety evaluation included the following: determinations of vital signs and clinical laboratory tests on days 1 (including prior to drug administration), 2, 4, 10, and 13; a physical examination on day 13; 12-lead ECG on days 10 and 13; and 24-h Holter monitoring on day 10. Each subject was observed after every dose of the study drug and throughout the postdosing period for possible adverse events (AEs).

Blood samples of 5 ml were obtained from the arm contralateral to the infusion site at 0 (immediately prior to study drug administration), 0.5, 1, 1.5, 2, 2.5, 3, 4, 8, 12, 24, 36, 48, 60, and 72 h after the start of study drug administration on days 1 and 10. In addition, blood samples were obtained immediately prior to dosing on days 5 through 9. Blood samples were collected in heparinized tubes and centrifuged; the plasma was separated and frozen at −20°C until it was assayed.

Concentrations of levofloxacin in plasma were assayed using validated high-performance liquid chromatography methodology (14) at PPD Development Inc., Middleton, Wisc. The assay was validated over the concentration ranges of 0.125 to 13.75 μg/ml (plasma), and the intraday precision values (as expressed by percent coefficient of variation) were <12%, while the corresponding interday precision values were <9%.

Pharmacokinetic analysis was performed as described previously (3, 9). Compartmental analysis utilized a linear dispositional model with first-order elimination from the central compartment (Win Nonlin, version 1.1; Scientific Consulting, Inc., Apex, N. C.). Estimated parameters included peak drug concentration in plasma (C_{max}), trough drug concentration in plasma (C_{min}), area under the concentration-versus-time curve (AUC), terminal disposition half-life (t_{1/2}), total body clearance (CL), and steady-state volume of distribution (V_{ss}). Data sets analyzed included data collected on days 1 through 3, 10 through 13, and 1 through 13. Model selection was based on the Akaike Information Criterion (1), and the sum of squared residuals was minimized using the Gauss-Newton algorithm with Levenberg and Hartley modification (5). Accumulation of levofloxacin following multiple dosing was estimated as the ratio of C_{max} at steady state (day 10) to C_{max} following the single dose (day 1) and as the ratio of AUC_{0–24} on day 10 to AUC_{0–24} on day 1.

Levofloxacin is eliminated primarily through the kidneys;
therefore, the renal function of each subject was estimated. Creatinine clearance (CL\text{cr}) was calculated by the Cockcroft and Gault method (4) using the baseline serum creatinine value of the subject and was employed as an index of each subject’s renal function.

Page’s test was used to test for attainment of steady-state conditions following once-daily dosing, using $C_{\text{min}}$ data from days 5 through 10 and the 24-h plasma concentration value after day 10 (multiple dosing) (13).

Equal percentages of men and women were enrolled in the study. The majority of subjects (83%) randomized to receive a placebo were Hispanic; subjects randomized to receive levofloxacin were Caucasian (42%) and Hispanic (50%). Subjects who received a placebo were younger (mean age, 35.7 years) than subjects who received levofloxacin (mean age, 41.2 years).

All 18 subjects completed study participation. Four (33%) of the 12 levofloxacin recipients and 3 (50%) of the 6 placebo recipients reported one or more treatment-emergent AEs. In the levofloxacin group, this included two cases each of peripheral edema at the infusion site and erythematous rash at the infusion site and one case each of dizziness, headache, pruritus at the infusion site, infusion site reaction, and euphoria. In the placebo group, the AEs included two cases of headache and one case each of peripheral edema at the infusion site, dizziness, infusion site edema, and purpura. All of these events were mild in nature and transient. No clinically significant alterations in clinical laboratory evaluations, vital sign measurements, physical-examination findings, 12-lead ECG, or 24-h Holter monitor findings were noted over the course of the study.

The mean plasma concentration-versus-time curve for the levofloxacin recipients is illustrated in Fig. 1. Based on Akaike Information Criterion values, a two-compartment model was selected to characterize the levofloxacin plasma concentration-versus-time data. For the 12 volunteers randomized to receive levofloxacin, a mean (± standard deviation [SD]) peak concentration of levofloxacin in plasma of 11.3 ± 3.6 and 12.4 ± 3.9 mg/ml was observed on days 1 and 10, respectively.

**TABLE 1. Summary of levofloxacin pharmacokinetic parameters for all volunteers, including subjects with differing renal function, using a two-compartment model\(^a\)**

<table>
<thead>
<tr>
<th>Subject group(^b) and dosage</th>
<th>C(_{\text{max}}) (µg/ml)</th>
<th>C(_{\text{min}}) (µg/ml)</th>
<th>AUC(_{\text{0-24}}) (µg·h/ml)</th>
<th>AUC(_{\text{0-24-12}}) (µg·h/ml)</th>
<th>$t_{1/2}$ (h)</th>
<th>CL (ml/min)</th>
<th>$V_{\text{ss}}$ (liters)</th>
<th>$C_{\text{max}}$ ratio</th>
<th>AUC(_{\text{0-24}}) ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>CL(_{\text{CR}}) &gt; 80 ml/min (n = 4)</td>
<td>8.12 ± 0.99</td>
<td>0.62 ± 0.11</td>
<td>61.1 ± 1.3</td>
<td>67.4 ± 1.75</td>
<td>6.91 ± 0.83</td>
<td>186 ± 5</td>
<td>106 ± 12</td>
<td>1.07 ± 0.03</td>
<td>1.10 ± 0.03</td>
</tr>
<tr>
<td>Single dose (day 1)</td>
<td>7.81 ± 0.90</td>
<td>0.68 ± 0.15</td>
<td>67.4 ± 1.75</td>
<td>74.3 ± 3.9</td>
<td>7.82 ± 1.76</td>
<td>107 ± 21</td>
<td>69.0 ± 16.7</td>
<td>1.11 ± 0.05</td>
<td>1.14 ± 0.08</td>
</tr>
<tr>
<td>Steady state (day 10)</td>
<td>12.9 ± 3.3</td>
<td>1.28 ± 0.47</td>
<td>106 ± 23</td>
<td>121 ± 28</td>
<td>139 ± 35</td>
<td>7.54 ± 1.54</td>
<td>133 ± 42</td>
<td>81.2 ± 23.3</td>
<td>1.10 ± 0.05</td>
</tr>
<tr>
<td>CL(_{\text{CR}}) ≤ 80 ml/min (n = 8)</td>
<td>14.2 ± 3.4</td>
<td>1.48 ± 0.61</td>
<td>121 ± 28</td>
<td>139 ± 35</td>
<td>7.51 ± 1.54</td>
<td>133 ± 42</td>
<td>81.2 ± 23.3</td>
<td>1.10 ± 0.05</td>
<td>1.13 ± 0.07</td>
</tr>
<tr>
<td>Single dose (day 1)</td>
<td>12.4 ± 3.9</td>
<td>1.21 ± 0.63</td>
<td>103 ± 35</td>
<td>117 ± 42</td>
<td>7.51 ± 1.54</td>
<td>133 ± 42</td>
<td>81.2 ± 23.3</td>
<td>1.10 ± 0.05</td>
<td>1.13 ± 0.07</td>
</tr>
<tr>
<td>Steady state (day 10)</td>
<td>11.3 ± 3.6</td>
<td>1.06 ± 0.50</td>
<td>90.9 ± 28.9</td>
<td>103 ± 35</td>
<td>7.51 ± 1.54</td>
<td>133 ± 42</td>
<td>81.2 ± 23.3</td>
<td>1.10 ± 0.05</td>
<td>1.13 ± 0.07</td>
</tr>
</tbody>
</table>

\(^a\) Data are presented as means ± SD. $C_{\text{max}}$ ratio, ratio of $C_{\text{max}}$ at steady state to $C_{\text{max}}$ following the single dose; AUC\(_{\text{0-24}}\) ratio, ratio of AUC\(_{\text{0-24}}\) on day 10 to AUC\(_{\text{0-24}}\) on day 1.

\(^b\) n, number of subjects.
steady state was achieved by day 2. The $C_{\text{max}}$ and the AUC at steady state were predictable based on 500-mg i.v. dosing (2). The pharmacokinetic profiles for oral versus parenteral administration of 750-mg doses were similar. The 100% bioavailability of oral levofloxacin allows for convenient conversion from i.v. dosing to oral dosing.

For patients with reduced renal function, levofloxacin $C_{\text{max}}$, AUC, and $t_{1/2b}$ values are known to increase (8). Since more than 80% of levofloxacin is eliminated unchanged in the urine, this observation is not surprising and allows for reduced dosing in patients with renal impairment. In the present study, the variation in pharmacokinetic parameters appeared to be related to renal function and body weight. Subjects having reduced renal function ($CL_{\text{cr}}$ of $\leq$80 ml/min) have higher $C_{\text{max}}$, AUC, and $t_{1/2b}$ values than subjects with $CL_{\text{cr}}$ values of $>80$ ml/min. No increase in drug retention was observed, and pharmacokinetics remained linear.

The higher $C_{\text{max}}$ and AUC/MIC ratios achieved with the higher dosing allow greater confidence in treating patients who may be infected with organisms for which levofloxacin MICs are high. In addition, patients with limited tissue perfusion secondary to compromised vascularity would benefit from receiving 750 mg of levofloxacin to treat infections such as complicated skin and skin structure infections, bacterial endocarditis, and nosocomial pneumonia.

Parenteral levofloxacin at the 750-mg dose level was well tolerated by the healthy volunteers, with mild and transient i.v.-site reactions predominating among the treatment-emergent AEs. These findings are consistent with the excellent safety profile of levofloxacin. Further studies are needed, however, to confirm these results with seriously ill patients receiving the higher (750-mg) dose. The results of this study support the clinical evaluation of a high-dose i.v. regimen to treat serious infection.

REFERENCES

